Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 14,602	$ 21,304
Prepaid expenses and other current assets	1,045	1,118
Total current assets	15,647	22,422
Long-term assets
Property and equipment, net	26	33
Operating lease right-of-use assets	131	421
Intangible assets, net	10,693	12,637
Other long-term assets		40
Total assets	26,497	35,553
Current liabilities
Accounts payable,net	1,777	3,254
Accrued compensation	1,675	728
Accrued clinical trial site costs	3,222	3,420
Operating lease liabilities	155	282
Other current liabilities	484	323
Total current liabilities	7,313	8,007
Long-term liabilities
Contingent liability for Essentialis purchase price	8,835	9,547
Long-term lease liabilities	0	175
Total liabilities	16,149	17,760
Commitments and contingencies (Note 8)
Stockholders’ equity
Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding
Common stock, $0.001 par value, 100,000,000 shares authorized, 8,159,382 and 5,324,287 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively.	8	80
Additional paid-in-capital	247,762	231,068
Accumulated deficit	(237,422)	(213,355)
Total stockholders' equity (deficit)	10,348	17,793
Total liabilities and stockholders'equity (deficit)	26,497	35,553
2018 PIPE Warrant Liability [Member]
Long-term liabilities
Warrant liability	$ 1	$ 31